Loading...
•
Jun 30, 2023
Relmada Q2 2023 Earnings Report
Announced second quarter 2023 financial results and provided a corporate update.
Key Takeaways
Relmada Therapeutics reported their Q2 2023 earnings, highlighting the ongoing Phase 3 clinical development plan for REL-1017 and anticipating data readouts from both Phase 3 trials in 2024. The company also stated that they are sufficiently funded to execute their plans.
Enrollment in the Reliance II (study 302) is progressing as expected, with completion anticipated in the first half of 2024.
The Relight Phase 3 Study (study 304) has been initiated, with screening ongoing, and completion is anticipated in the second half of next year.
The one-year, open-label safety study, Reliance-OLS (study 310), with REL-1017 was recently completed, and data availability is expected during the current quarter.
The company is sufficiently funded to reach data readouts from both Phase 3 trials, Reliance (study 302) and Relight (study 304), in 2024.
Relmada
Relmada
Forward Guidance
Relmada Therapeutics is focused on the clinical development of REL-1017 and anticipates data readouts from Phase 3 trials in 2024.
Positive Outlook
- Enrollment in Reliance II is progressing as expected.
- Relight Phase 3 study has been initiated and screening is ongoing.
- Reliance-OLS study was recently completed.
- Data availability from Reliance-OLS is expected during the current quarter.
- Sufficient funding to reach data readouts from Phase 3 trials.
Challenges Ahead
- Potential failure of clinical trial results to demonstrate statistically and/or clinically significant evidence of efficacy and/or safety
- Failure of top-line results to accurately reflect the complete results of the trial
- Failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder
- Risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements
- Inability to predict or identify all the risks, uncertainties and other factors that may affect future results